|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003250,
umls-concept:C0003873,
umls-concept:C0008976,
umls-concept:C0025677,
umls-concept:C0027540,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0086418,
umls-concept:C0087111,
umls-concept:C0205177,
umls-concept:C0205210,
umls-concept:C0205245,
umls-concept:C0521115,
umls-concept:C1122087,
umls-concept:C1274040,
umls-concept:C1521761
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2004-5-17
|
|
pubmed:abstractText |
Tumor necrosis factor (TNF) is an important proinflammatory cytokine that mediates inflammatory synovitis and articular matrix degradation in rheumatoid arthritis (RA). We investigated the ability of adalimumab, a human anti-TNF monoclonal antibody, to inhibit the progression of structural joint damage, reduce the signs and symptoms, and improve physical function in patients with active RA receiving concomitant treatment with methotrexate (MTX).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
50
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1400-11
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:15146409-Activities of Daily Living,
pubmed-meshheading:15146409-Adult,
pubmed-meshheading:15146409-Aged,
pubmed-meshheading:15146409-Antibodies, Monoclonal,
pubmed-meshheading:15146409-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:15146409-Antirheumatic Agents,
pubmed-meshheading:15146409-Arthritis, Rheumatoid,
pubmed-meshheading:15146409-Drug Therapy, Combination,
pubmed-meshheading:15146409-Female,
pubmed-meshheading:15146409-Humans,
pubmed-meshheading:15146409-Male,
pubmed-meshheading:15146409-Methotrexate,
pubmed-meshheading:15146409-Middle Aged,
pubmed-meshheading:15146409-Placebos,
pubmed-meshheading:15146409-Quality of Life,
pubmed-meshheading:15146409-Recovery of Function,
pubmed-meshheading:15146409-Treatment Outcome,
pubmed-meshheading:15146409-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial.
|
|
pubmed:affiliation |
University of Toronto, Toronto, Ontario M5G 1X5, Canada.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
